loading...| Preferred Name |
nintedanib |
|
| Synonyms |
Tyrosine Kinase Inhibitor BIBF 1120 |
|
| Definitions |
An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62765" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62765" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000504524 |
|
| altLabel |
Tyrosine Kinase Inhibitor BIBF 1120 intedanib BIBF 1120 Vargatef methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate multitargeted tyrosine kinase inhibitor BIBF 1120 BIBF-1120 |
|
| cui |
C2700098 C1879771 C2930789 |
|
| DATE FIRST PUBLISHED |
2006-08-24 |
|
| Date last modified |
2015-11-04 |
|
| definition |
An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62765" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62765" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C62765 |
|
| notation |
CDR0000504524 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
nintedanib |
|
| tui |
T109 T121 |